Author

Genevieve Jehl

Observed names: G Jehl, G. Jehl

Institution: Merck Serono S.A.S. (France)

Observed institutions: Merck KGaA, Darmstadt (Germany), Merck Serono S.A.S. (France), Merck Healthcare KGaA, Darmstadt (Germany)

OpenAlex ID: A5086355128

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

2020 · Julius Strauss, Margaret E Gatti-Mays, et al. · Journal for ImmunoTherapy of Cancer · 153

Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure

2024 · Michael Birrer, Guiling Li, et al. · JAMA Oncology · 34

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

2022 · Alexander Spira, Michael S Wertheim, et al. · The Oncologist · 34

Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies.

2021 · Julius Strauss, Fadi S. Braiteh, et al. · Journal of Clinical Oncology · 16

Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC

2024 · Ho Yeong Lim, Jeong Heo, et al. · Hepatology · 7

957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

2021 · J. Strauss, M. Gatti-Mays, et al. · Annals of Oncology · 7

879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer

2020 · M.J. Birrer, L.R. Mileshkin, et al. · Annals of Oncology · 6

Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.

2022 · Ana Oaknin, Sharad A. Ghamande, et al. · Journal of Clinical Oncology · 3

P-133 Clinical responses in pancreaticobiliary cancer patients who received bintrafusp alfa (BA) or BA plus CXCR1/2 inhibitor (SX-682) plus CEA/MUC1-targted vaccine (CV301)

2022 · J. Redman, A. Spira, et al. · Annals of Oncology · 2

917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer

2021 · A Oaknin, M Gil-Martin, et al. · Cervical cancer · 2

PO:11:286 Design of a phase 3, randomised, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in cutaneous manifestations of lupus with or without systemic disease

2026 · Eric Morand, J Michelle Kahlenberg, et al.

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for recurrent/metastatic cervical cancer after platinum failure: primary results from a phase 2 study

2023 · Gui-Ling Li, Mayu Yunokawa, et al. · Research Square

116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies

2021 · J. Strauss, F. Braiteh, et al. · International Journal of Gynecological Cancer

Works count: 13

Citation count: 264

H-index: 6

I10-index: 4